NOW FDA APPROVED1
Introducing COBENFY: the first new class* of treatment in over 3 decades for adult patients with schizophrenia1-4
The first and only M1/M4 muscarinic agonist1,3,5*
COBENFY will be available starting October 25th
*COBENFY is a combination of xanomeline (M1/M4 muscarinic agonist) and trospium chloride (muscarinic antagonist).1
Register for the COBENFY National Launch Broadcast on October 25th
COBENFY will be available starting October 25th